Skip to content
Evigrade
ModerateDirect oral anticoagulants (factor Xa inhibitors)×Other opioids

Updated · Methodology

Mechanism

Edoxaban is a direct inhibitor of clotting factor Xa and by itself increases the bleeding risk (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA, sections 4.4 and 5.1). Drugs that affect haemostasis may increase this risk, and the edoxaban documents list serotonin and noradrenaline reuptake inhibitors (SNRIs) among them. As with other anticoagulants, the bleeding risk with SNRIs may be higher because of their reported effect on platelets (EMA, sections 4.4 and 4.5; edoxaban label, US Food and Drug Administration, FDA, section 7.1). Tramadol is an opioid that, according to its US label, also weakly inhibits the reuptake of serotonin and noradrenaline (tramadol FDA label, sections 5.7 and 12.1). The documents do not address the combination of edoxaban and tramadol directly. The tramadol documents discuss bleeding only in connection with warfarin and other coumarins (tramadol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). The documents also say nothing about either drug changing the levels of the other. Edoxaban is a substrate of the transporter P-glycoprotein (P-gp) and circulates mainly unchanged. CYP3A4 metabolises only a small part of it, and about half of its clearance is renal. The edoxaban documents do not list tramadol among P-gp inhibitors or inducers. In vitro, edoxaban did not inhibit CYP2D6 or CYP3A4, which metabolise tramadol (EMA, sections 4.5 and 5.2; FDA, section 12.3; AEMPS, section 5.2).

Symptoms

The documents describe no symptoms linked to this combination. The main risk of edoxaban is bleeding. The most frequent adverse reactions are nosebleeds (7.7%), blood in the urine (6.9%) and anaemia (5.3%). Bleeding can occur at any site and can be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA, section 4.8; edoxaban label, US Food and Drug Administration, FDA, section 5.3). The most frequent adverse effects of tramadol are nausea and dizziness, seen in more than 10% of patients. Headache, drowsiness, constipation, dry mouth, vomiting and sweating are common (tramadol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.8).

Management

The documents do not address this combination directly. The edoxaban documents list serotonin and noradrenaline reuptake inhibitors (SNRIs) among the drugs that affect haemostasis and may increase the bleeding risk. Edoxaban is used with caution in people at increased risk of bleeding (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA, sections 4.4 and 4.5). Tramadol, according to its US label, weakly inhibits the reuptake of serotonin and noradrenaline (tramadol label, US Food and Drug Administration, FDA, section 5.7). The combination is therefore managed with the same caution. Any signs or symptoms of blood loss are evaluated promptly (edoxaban FDA label, section 5.3), and edoxaban is stopped if severe bleeding occurs (EMA, section 4.4). An unexplained fall in haemoglobin or blood pressure calls for a search for a bleeding site (EMA, section 4.4). The documents give no reason to change the edoxaban dose. Among concomitant drugs, only certain inhibitors of the transporter P-glycoprotein (P-gp), named explicitly in the SmPC, require a reduction to 30 mg. Tramadol is not among them (EMA, section 4.5).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Edoxaban

Other interactions with Tramadol